Literature DB >> 21771976

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.

Øystein L Holla1, Jamie Cameron, Kristian Tveten, Thea Bismo Strøm, Knut Erik Berge, Jon K Laerdahl, Trond P Leren.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low density lipoprotein receptor (LDLR) at the cell surface and disrupts the normal recycling of the LDLR. In this study, we investigated the role of the C-terminal domain for the activity of PCSK9. Experiments in which conserved residues and histidines on the surface of the C-terminal domain were mutated indicated that no specific residues of the C-terminal domain, apart from those responsible for maintaining the overall structure, are required for the activity of PCSK9. Rather, the net charge of the C-terminal domain is important. The more positively charged the C-terminal domain, the higher the activity toward the LDLR. Moreover, replacement of the C-terminal domain with an unrelated protein of comparable size led to significant activity of the chimeric protein. We conclude that the role of the evolutionary, poorly conserved C-terminal domain for the activity of PCSK9 reflects its overall positive charge and size and not the presence of specific residues involved in protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771976      PMCID: PMC3173001          DOI: 10.1194/jlr.M018093

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  21 in total

1.  Structure of the LDL receptor extracellular domain at endosomal pH.

Authors:  Gabby Rudenko; Lisa Henry; Keith Henderson; Konstantin Ichtchenko; Michael S Brown; Joseph L Goldstein; Johann Deisenhofer
Journal:  Science       Date:  2002-11-29       Impact factor: 47.728

Review 2.  Endocytic recycling.

Authors:  Frederick R Maxfield; Timothy E McGraw
Journal:  Nat Rev Mol Cell Biol       Date:  2004-02       Impact factor: 94.444

3.  Anomalous behaviour of a protein during SDS/PAGE corrected by chemical modification of carboxylic groups.

Authors:  A Matagne; B Joris; J M Frère
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

4.  Retention of mutant low density lipoprotein receptor in endoplasmic reticulum (ER) leads to ER stress.

Authors:  Stine Sørensen; Trine Ranheim; Kari Solberg Bakken; Trond P Leren; Mari Ann Kulseth
Journal:  J Biol Chem       Date:  2005-10-28       Impact factor: 5.157

5.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Authors:  Jamie Cameron; Øystein L Holla; Trine Ranheim; Mari Ann Kulseth; Knut Erik Berge; Trond P Leren
Journal:  Hum Mol Genet       Date:  2006-03-28       Impact factor: 6.150

6.  Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.

Authors:  David Cunningham; Dennis E Danley; Kieran F Geoghegan; Matthew C Griffor; Julie L Hawkins; Timothy A Subashi; Alison H Varghese; Mark J Ammirati; Jeffrey S Culp; Lise R Hoth; Mahmoud N Mansour; Katherine M McGrath; Andrew P Seddon; Shirish Shenolikar; Kim J Stutzman-Engwall; Laurie C Warren; Donghui Xia; Xiayang Qiu
Journal:  Nat Struct Mol Biol       Date:  2007-04-15       Impact factor: 15.369

7.  Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor.

Authors:  Øystein L Holla; Jon K Laerdahl; Thea Bismo Strøm; Kristian Tveten; Jamie Cameron; Knut Erik Berge; Trond P Leren
Journal:  Biochem Biophys Res Commun       Date:  2011-02-13       Impact factor: 3.575

8.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.

Authors:  Nabil G Seidah; Suzanne Benjannet; Louise Wickham; Jadwiga Marcinkiewicz; Stephanie Belanger Jasmin; Stefano Stifani; Ajoy Basak; Annik Prat; Michel Chretien
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

9.  The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.

Authors:  Derek E Piper; Simon Jackson; Qiang Liu; William G Romanow; Susan Shetterly; Stephen T Thibault; Bei Shan; Nigel P C Walker
Journal:  Structure       Date:  2007-05       Impact factor: 5.006

10.  Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.

Authors:  Øystein L Holla; Jamie Cameron; Knut Erik Berge; Trine Ranheim; Trond P Leren
Journal:  BMC Cell Biol       Date:  2007-03-01       Impact factor: 4.241

View more
  21 in total

1.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

Review 2.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

3.  The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.

Authors:  Delia Susan-Resiga; Emmanuelle Girard; Robert Scott Kiss; Rachid Essalmani; Josée Hamelin; Marie-Claude Asselin; Zuhier Awan; Chutikarn Butkinaree; Alexandre Fleury; Armand Soldera; Yves L Dory; Alexis Baass; Nabil G Seidah
Journal:  J Biol Chem       Date:  2016-12-20       Impact factor: 5.157

4.  An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.

Authors:  Kévin Ly; Rachid Essalmani; Roxane Desjardins; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

5.  Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

Authors:  Kévin Ly; Yascara Grisel Luna Saavedra; Maryssa Canuel; Sophie Routhier; Roxane Desjardins; Josée Hamelin; Janice Mayne; Claude Lazure; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

6.  Small Molecule Inhibitors of the PCSK9·LDLR Interaction.

Authors:  Jaru Taechalertpaisarn; Bosheng Zhao; Xiaowen Liang; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2018-02-26       Impact factor: 15.419

7.  The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.

Authors:  Yascara Grisel Luna Saavedra; Robert Day; Nabil G Seidah
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

8.  PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.

Authors:  Kristian Tveten; Thea Bismo Str M; Knut Erik Berge; Trond P Leren
Journal:  J Lipid Res       Date:  2013-03-18       Impact factor: 5.922

9.  Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.

Authors:  Yingnan Zhang; Charles Eigenbrot; Lijuan Zhou; Steven Shia; Wei Li; Clifford Quan; Jeffrey Tom; Paul Moran; Paola Di Lello; Nicholas J Skelton; Monica Kong-Beltran; Andrew Peterson; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2013-11-13       Impact factor: 5.157

10.  Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.

Authors:  Yan Wang; Yongcheng Huang; Helen H Hobbs; Jonathan C Cohen
Journal:  J Lipid Res       Date:  2012-07-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.